PE27899A1 - Formulacion de particulas revestidas - Google Patents

Formulacion de particulas revestidas

Info

Publication number
PE27899A1
PE27899A1 PE1997000854A PE00085497A PE27899A1 PE 27899 A1 PE27899 A1 PE 27899A1 PE 1997000854 A PE1997000854 A PE 1997000854A PE 00085497 A PE00085497 A PE 00085497A PE 27899 A1 PE27899 A1 PE 27899A1
Authority
PE
Peru
Prior art keywords
formulation
preference
methyl
polymer
wax
Prior art date
Application number
PE1997000854A
Other languages
English (en)
Inventor
Tommy Clifford Morris
Hans Joerg Lange
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE27899A1 publication Critical patent/PE27899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A UNA FORMULACION ORAL SOLIDA EN GRANULOS O TABLETAS QUE NO REQUIEREN REVESTIMIENTO INTERIOR, QUE COMPRENDE: 2-METIL-4-(4-METIL-1-PIPERAZINIL)-1OH-TIENO[2,3-b][1,5] BENZODIACEPINA (OLANZAPINA) REVESTIDA CON UN POLIMERO; DE PREFERENCIA SE UTILIZA LA FORMA ANHIDRA MAS ESTABLE O LA FORMA (II) DE OLANZAPINA CARACTERIZADO SEGUN SUS ESPACIOS INTERPLANARES (d) MEDIDOS EN EL DIFRACTOMETRO DE RAYOS X : 10,2689 8,577 7,4721 7,125 6,1425 6,071 5,4849 5,2181 5,1251 4,9874 4,7665 4,7158 4,4787 4,3307 4,2294 4,141 3,9873 3,7206 3,5645 3,5366 3,3828 3,2516 3,134 3,0848 3,0638 3,0111 2,8739 2,8102 2,7217 2,6432 2,6007; EL POLIMERO SE SELECCIONA DE ALCOHOL CETILICO, CERA DE ESTERES CETILICOS, CERA DE CARNAUBA, GOMA, CERA DE ABEJAS, ESTEARATO DE MAGNESIO, ENTRE OTROS, DE PREFERENCIA ES HIDROXIPROPILMETILCELULOSA LIBRE DE POLIETILENGLICOL. ESTA FORMULACION PRESENTA UN COLOR Y ASPECTO PERSISTENTE, SIENDO UTIL EN EL TRATAMIENTO PSICOTICO
PE1997000854A 1996-09-24 1997-09-23 Formulacion de particulas revestidas PE27899A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2663396P 1996-09-24 1996-09-24

Publications (1)

Publication Number Publication Date
PE27899A1 true PE27899A1 (es) 1999-03-12

Family

ID=21832952

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000854A PE27899A1 (es) 1996-09-24 1997-09-23 Formulacion de particulas revestidas

Country Status (21)

Country Link
US (1) US20010020032A1 (es)
EP (1) EP0830858A1 (es)
JP (1) JP2001501207A (es)
KR (1) KR20000048540A (es)
CN (1) CN1230883A (es)
AR (1) AR009802A1 (es)
AU (1) AU719788B2 (es)
BR (1) BR9713215A (es)
CA (1) CA2266448A1 (es)
CO (1) CO4910139A1 (es)
CZ (1) CZ98899A3 (es)
EA (1) EA001610B1 (es)
HU (1) HUP9904065A3 (es)
ID (1) ID21762A (es)
IL (1) IL128845A0 (es)
NO (1) NO991405L (es)
PE (1) PE27899A1 (es)
PL (1) PL332503A1 (es)
TR (1) TR199900651T2 (es)
WO (1) WO1998013027A1 (es)
ZA (1) ZA978517B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
TWI275394B (en) * 2000-01-26 2007-03-11 Asahi Chemical Corp Mizoribin tablet improved with color tone change
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SI21303A (sl) * 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
US20070218139A1 (en) 2002-12-20 2007-09-20 Smith Thomas J High Pressure Compaction For Pharmaceutical Formulations
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
ES2303462B1 (es) 2004-09-06 2009-06-05 Shasun Chemicals And Drugs Limited Nuevo procedimiento para la preparacion de una forma polimorfica i de olanzapina farmaceuticamente pura.
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
ATE465720T1 (de) * 2006-07-05 2010-05-15 Bilim Ilac Sanayii Ve Ticaret Stabile olanzapin-formulierung mit antioxidantien
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
SI2563763T1 (sl) * 2010-04-30 2015-03-31 Bristol-Myers Squibb Company Farmacevtski sestavki, ki obsegajo N-(4-(2-amino-3-kloropiridin-4-iloksi)-3-fluorofenil)-4-etoksi-L-(4- fluorofenil)-2-okso-1,2-dihidropiridin-3-karboksamid
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
EP2976062B1 (en) 2013-03-21 2021-11-03 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
CN108289857A (zh) 2015-10-27 2018-07-17 优普顺药物公司 局部麻醉药的持续释放制剂
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
KR20200110648A (ko) 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 비라세믹 혼합물 및 이의 용도
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
NZ247703A (en) * 1992-05-29 1995-07-26 Lilly Industries Ltd Thienobenzdiazepine derivatives and medicaments thereof
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5637584A (en) * 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine
IL117612A0 (en) * 1995-03-24 1996-07-23 Lilly Co Eli Granule formulation for olanzapine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina

Also Published As

Publication number Publication date
AU4423097A (en) 1998-04-17
IL128845A0 (en) 2000-01-31
WO1998013027A1 (en) 1998-04-02
HUP9904065A2 (hu) 2000-04-28
ZA978517B (en) 1999-03-23
BR9713215A (pt) 2000-04-04
JP2001501207A (ja) 2001-01-30
AR009802A1 (es) 2000-05-03
EP0830858A1 (en) 1998-03-25
PL332503A1 (en) 1999-09-13
TR199900651T2 (xx) 1999-07-21
EA001610B1 (ru) 2001-06-25
EA199900331A1 (ru) 2000-04-24
HUP9904065A3 (en) 2001-10-29
US20010020032A1 (en) 2001-09-06
NO991405D0 (no) 1999-03-23
ID21762A (id) 1999-07-22
CA2266448A1 (en) 1998-04-02
KR20000048540A (ko) 2000-07-25
CZ98899A3 (cs) 1999-12-15
CN1230883A (zh) 1999-10-06
NO991405L (no) 1999-03-23
CO4910139A1 (es) 2000-04-24
AU719788B2 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
PE27899A1 (es) Formulacion de particulas revestidas
CA2059316A1 (en) Air freshener device with visual signal means
HUP9800410A2 (hu) Szájon át adható 2-metil-tieno-benzodiazepin-készítmény
PT841956E (pt) Artigo absorvente descartavel tendo uma camada superior com uma locao contendo um emoliente e um agente imobilizante de poliester de poliol
AR023299A1 (es) UNA FORMULACION DE LIBERACION PROLONGADA DE UN COMPUESTO MACRoLIDO
EP1245231A3 (en) Pharmaceutical formulations containing darifenacin
PL327491A1 (en) Simeticone and anhydrous calcium phosphate containing composition
BR0113067A (pt) Forma de dosagem de drogas à base de hidrogel
ID24479A (id) Eter-eter diaril dan proses pembuatannya serta komposisi-komposisi herbisida serta pengering yang mengandung eter diaril
DE69637669D1 (de) Myogene differenzierung menschlicher mesenchymaler stammzellen
HUP9601161A3 (en) Use of retinoids in cosmetic compositions or for the manufacture of pharmaceutical compositions
KR20040019070A (ko) 겔 공기 청정 장치
BR9704559A (pt) Película com camada de substrato contendo agente de antibloqueio
BR9508559A (pt) Processo de descontaminação de um ambiente processo de esterlização de superfídie fria processo de desinfecção composiçao superficie sólida substancialmente não-porosa e superfície sólida revestida com um resíduo
BR0006072A (pt) Composição impermeável à água, processos e aplicações da mesma
MY116421A (en) New formulation
IL117613A (en) Lower alcohol solvates of olanzapine and the preparation therefrom of technical grade olanzapine
AU8784798A (en) Air freshener dispenser device with taper candle feature
NO982700D0 (no) Mikrobiell 11<alfa>-hydroksylering av steroider
NO960826D0 (no) Anvendelse av enzymer fra krill i forstoffer
FR2745500B1 (fr) Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
AU129006S (en) Hitch ball
BR9602664A (pt) Recipiente oco de plástico tendo um acabamento com um diâmetro menor de que o corpo do recipiente
IL117612A0 (en) Granule formulation for olanzapine
GR3003917T3 (es)

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed